8IG0

Crystal structure of menin in complex with DS-1594b

Summary for 8IG0

• Entry DOI: 10.2210/pdb8ig0/pdb
• Descriptor: Menin, (1R,2S,4R)-4-[[4-(5,6-dimethoxypyridazin-3-yl)phenyl]methylamino]-2-[methyl-[6-[2,2,2-tris(fluoranyl)ethyl]thieno[2,3-d]pyrimidin-4-yl]amino]cyclopentan-1-ol, UNKNOWN ATOM OR ION, ... (5 entities in total)
• Functional Keywords: leukemia, transcription-inhibitor complex, transcription/inhibitor
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 4
• Total formula weight: 247032.41

Authors

Suzuki, M.,Yoneyama, T.,Imai, E. (deposition date: 2023-02-20, release date: 2023-03-22, Last modification date: 2023-09-20)

Primary citation

Numata, M.,Haginoya, N.,Shiroishi, M.,Hirata, T.,Sato-Otsubo, A.,Yoshikawa, K.,Takata, Y.,Nagase, R.,Kashimoto, Y.,Suzuki, M.,Schulte, N.,Polier, G.,Kurimoto, A.,Tomoe, Y.,Toyota, A.,Yoneyama, T.,Imai, E.,Watanabe, K.,Hamada, T.,Kanada, R.,Watanabe, J.,Kagoshima, Y.,Tokumaru, E.,Murata, K.,Baba, T.,Shinozaki, T.,Ohtsuka, M.,Goto, K.,Karibe, T.,Deguchi, T.,Gocho, Y.,Yoshida, M.,Tomizawa, D.,Kato, M.,Tsutsumi, S.,Kitagawa, M.,Abe, Y.
A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Cancer Cell Int, 23:36-36, 2023

PubMed Abstract: Mixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin‒MLL1 complex. Small-molecule-mediated inhibition of the protein‒protein interaction between Menin and MLL1 fusion proteins is a potential therapeutic strategy for patients with MLL1-r or mutated-nucleophosmin 1 (NPM1c) acute leukemia. In this study, we preclinically evaluated the new compound DS-1594a and its salts.

PubMed: 36841758
DOI: 10.1186/s12935-023-02877-y

Experimental method

X-RAY DIFFRACTION (2.6 Å)